[Vancomycin resistant Enterococci (VRE)]

Nephrol Ther. 2009 Jun:5 Suppl 4:S261-4. doi: 10.1016/S1769-7255(09)74556-0.
[Article in French]

Abstract

Vancomycin resistant enteroccoci (VRE) has recently emerged in France and in Europe whereas it has been endemic in the United States for two decades. Despite its little pathogenicity, VRE may be responsible for severe, difficult to treat infections in immunocompromised host. Intestinal colonization precedes infection and is responsible for VRE silent dissemination. In case of epidemy, infection control measures should be quickly implemented to avoid endemicity.

Publication types

  • English Abstract

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Cross Infection / drug therapy*
  • Cross Infection / microbiology
  • Cross Infection / prevention & control
  • Enterococcus faecium / drug effects
  • Enterococcus faecium / pathogenicity*
  • Europe
  • France
  • Gram-Positive Bacterial Infections / complications
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / prevention & control
  • Humans
  • Immunocompromised Host*
  • Infection Control / methods
  • Vancomycin / pharmacology*
  • Vancomycin / therapeutic use
  • Vancomycin Resistance*

Substances

  • Anti-Bacterial Agents
  • Vancomycin